Charles University, Prague, Czech Republic
Zealand University Hospital Roskilde and Naestved, Denmark
-M.D. University of Copenhagen 1983.
-Specialist in Internal Medicine 1997.
-Doctor Medicinae, University of Copenhagen 1998.
Current and immediate past position:
-Head of Research, Chief Consultant and Professor in Clinical Oncology, Department of Clinical Oncology, Zealand University Hospital Roskilde, Denmark and the Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (2017-ongoing).
-Head of Research, Chief Consultant and Professor in Clinical Oncology, Department of Oncology, Odense University Hospital, and Clinical Institute, University of Southern Denmark (2007-2017).
-Doctoral thesis: “Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine” University of Copenhagen 1998.
-159 published papers including 54 as 1. author and 43 as senior author. Hirsch-index = 33.
Member International Working Groups
-Chair, Faculty on Supportive and Palliative Care, European Society for Medical Oncology, ESMO (2012-2016).
-Member, Faculty on Supportive and Palliative Care, ESMO (2016-ongoing).
-Member, Clinical Trials Unit, Nordic Society for Gynaecologic Oncology, NSGO (ongoing)
-Steering Committee MASCC and ESMO antiemetic guidelines group (1999-ongoing).
-Chair, ESMO Supportive Care Guidelines (2012-2016).
Board member International Societies
-Multinational Association of Supportive Care in Cancer, MASCC (1999-2012, 2013-2016).
-President of MASCC (2008-2010).
-Nordic Society of Gynaecologic Oncology, NSGO (2012-2016)
Reviewer and editorial activity
-Associate Editor-in Chief, Supportive Care in Cancer (2009-2016).
-Associate Editor, Supportive Care in Cancer (2001-2009 and 2016-ongoing)
-Member of the Editorial Board European Oncology and Hematology (2012-ongoing)
-Member of the Editorial Board ESMO Open (2017-ongoing)
-Reviewer activity for more than 15 international cancer journals
-Member of the Scientific Committee for more than 20 International Conferences.
Other scientific activities
-Chairman of the MASCC 10th International Symposium, Copenhagen 2001.
-Chairman of the MASCC/ISOO 24th International Symposium, Copenhagen 2015
-More than 60 invited international oral presentations (ASCO, ESMO, ECCO, MASCC, IASLC, UICC, World Congress Gastrointestinal Cancer, Japan Society of Clinical Oncology)
-Member, Assessment Committee for 4 national and 2 international professorships and 8 PhD theses.
-MASCC Supportive Care Berlin Award 2003
-Danish Oncology Award 2014
-MASCC Distinguished Service Award 2015
-Højesteretssagfører Kaj Bunch-Jensen og Allis Bunch-Jensens Legat 2018.
-17 master theses (kandidatspeciale) and 3 bachelor thesis at KU and SDU.
-10 PhD thesis (principal supervisor for 7), 7 completed and 3 ongoing.
Investigator Considerable experience in Good Clinical Practice (GCP) in terms of web-based courses and as local principal investigator (PI), national coordinator, Nordic coordinator (PI), global coordinator (PI) and sponsor of a number of multinational GCP trials.
Barts Cancer Institute, Queen Mary University London, UK
Professor Schmid is internationally recognized for his research and education leadership in breast cancer. He is the clinical director of the Breast Cancer Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He was appointed in 2013 as Chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University, London. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI, with a particular interest in Immunotherapy, innovative trial designs, and circulating biomarkers. He leads the academic breast cancer programme and the cancer immune therapy group at St. Bartholomew’s Hospital and BCI.
Prof Schmid graduated from the Technical University of Munich medical school in 1997, gaining a MD in Clinical Chemistry in 1998 from the University of Munich and a Clinical Research PhD in 2005 from Charité University in Berlin. He trained at the University Hospital Charité in Berlin in internal medicine, haematology, and oncology, before he became a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London in 2005. Professor Schmid was appointed as Foundation Chair in Cancer Medicine at the University of Sussex in 2010 before taking on his current role at Barts in 2013.
Professor Schmid’s primary research interest is in clinical research in breast cancer with the goal of improving the treatment of women with breast cancer by defining more effective and less toxic approaches. Specific research areas include cancer immune therapy, triple-negative breast cancer, endocrine resistance, and innovative biomarker-driven trial concepts. Professor Schmid runs an international collaborative clinical and translational research programme. He is the principal investigator of several pivotal breast cancer studies, including the Impassion130 trial that evaluated atezolizumab for advanced triple-negative breast cancer and led to the regulatory approval of the first immunotherapy strategy for patients with breast cancer in North America and Europe. His work has been published in many journals including the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Communications and the Journal of Clinical Oncology.
Prof Schmid is a member of several national and international cancer organisations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Peter Schmid is a member of the European Society for Medical Oncology (ESMO) breast cancer faculty.
Department of Medical Oncology, IRRCS Hospital San Martino, Genoa, Italy
1978 MD degree 110/110 cum laude, University of Genoa
1980 Postdoctoral Associate Med. Oncology, Yale University New Haven, USA
1983 Associate Research Scientist in Medical Oncology, Yale University New Haven, USA
1983 Specialization in Internal Medicine, University of Genoa
1984 Residency in Internal Medicine, Yale Affiliated Norwalk Hospital, USA
1985 Associate Research Scientist in Medical Oncology, Yale University New Haven, USA
1986 Assistant Professor in Medical Oncology, National Cancer Instiute, Genoa
1988 Specialization in Medical Oncology, University of Genoa
1990 Associate Professor in Medical Oncology, National Institute of Tumors, Genoa
1991 Assistant Professor in Medical Oncology, University of Florence
1991 – 1996 Associate Professor in Medical Oncology, University of Firenze
1997 – 2001 Chair, Medical Oncology, University of Udine
2000 – 2005 Coordinate of the Clinical Projects, Consiglio Nazinale Ricerche CNR
2000 – 2001 Director, Oncology Department, University of Udine/Osped. Civile
Since 2002 Head, Medical Oncology Unit, Hospital San Martino, Genoa
American Society of Clinical Oncology
American Association for Cancer Research
Associazione Italiana Oncologia Medica
European Society of Medical Oncology
Clinical Research Experience
During the past 5 years Dr. Sobrero’s group has conducted approximately 15 clinical trials/year, most of which Phase III trials on innovative targeted agents. The areas of investigation have been G.I., G.U., breast, NSCLC, GIST. Prof. Sobrero has also been the P.I. of a recent registration trial on cetuximab (the EPIC trial) in colorectal cancer.
University Medical Center Hamburg-Eppendorf, Germany
11/2005-2010 Clinical and research fellow at the department for oncology/hematology (Prof. Schmoll) Martin-Luther-University of Halle (participation in over 40 phase I to III-studies (gastrointestinal, hematological, neuroendocrine, thyroid, head and neck, germ cell cancer)
2006-present Study coordinator/Vice coordinating or coordinating investigator of several trial phase II and III trials e.g.
- TEX (IIT, single arm phase II, NCT00511446)
- PETACC 6 (EORTC-Intergroup, phase III, NCT00766155)
- DEBIRITUX (IIT, randomized, phase II, NCT01060423)
- CHARTA–AIO KRK 0209 (IIT, randomized phase II, NCT01321957)
- ACTICCA-1 (IIT, Intergroup, phase III-trial, NCT02170090)
- PERMAD (IIT, randomized phase II, NCT02331927)
- MODUL (randomized phase II, NCT02291289)
- SENTINEL (IIT, phase I, NCT02384850)
- AVETUX (IIT, phase II, NCT03174405)
- INTEGA (IIT, phase II, NCT03409848)
- CARE4CAYA (IIT, phase III)
Receipt of research grants by academic research programs, German Cancer Aid, Roche, Sanofi, Merck, BMS, GBA Innovationsfond for clinical and/or translational research
09/2010 Participation and development of ESMO Consensus guidelines on Colorectal Cancer (Lugano, 2010)
12/2010 Clinical research coordinator Hubertus Wald Tumorzentrum, University Cancer Center Hamburg (UCCH) (Prof. Dirk Arnold), and clinical fellow Department of Oncology, Haematology, Stem Cell Transplantation with the section Pneumology, (Prof. Carsten Bokemeyer) University Medical Center Hamburg-Eppendorf (UKE) for Gastrointestinal malignancies
2011-present Principal investigator (UKE) for several phase II trials in gastrointestinal malignancies and sarcoma
2012 – present Head of the Clinical trial core unit UCCH
2014 – present Senior physician/consultant at Department of Oncology, Haematology, Stem Cell Transplantation with the section Pneumology, University Medical Center Hamburg-Eppendorf (UKE)
2015 – present Associate professorship at UKE
2017 – present Associate director of the UCCH
since 03/2019 Partner in private practice (1)
Review of manuscripts for several oncological journals (e.g. BMC Cancer, Eur J Cancer, Colorectal Cancer, Annals of Oncology, Pharmacogenomics)
Membership and positions: ESMO (program committee for colorectal cancer track since 2016, ESMO faculty member for Gastro-Intestinal Tumours faculty group 2017-18), AIO (task force member within the working groups for colorectal and gastric cancer), DGHO (program committee for colorectal cancer track since 2015), EORTC, ASCO, ASORS, DGIM
Member of Data Safety Monitoring Board: POWER (NCT01627379), NEOLAP (NCT02125136)
2007 Protocol development course in Flims (Switzerland) sponsored by EORTC, AACR, ASCO
2011 ESMO Fellowship, Clinical Investigation and Research Unit, Brighton and Sussex University Hospitals NHS Trust (Aug-Sep 2011)
GCP trainings: 2006, 2010, 2011, 2013, 2016, 2017 last one 14th of December 2018
Jan van Meerbeeck
Antwerp University Hospital / University of Antwerp, Belgium
University Hospital Schleswig-Holstein, Kiel, Germany